Abbreviations used in this paper: BM, basement membrane; LN, laminin.

Introduction
============

The lung is a frequent site for metastasis of many different tumor types. Tumor cells enter the circulation from the primary tumor and then colonize distant organs. The interactions between the tumor cells and the vessels that allow the initial arrest of the tumor cell in the lung are poorly characterized, although in individual cases contributing molecules have been identified ([@bib1]; [@bib3]). Recently, we developed methods that allow the observation of the early events in metastasis after entry of the cells into the pulmonary circulation ([@bib6]). Fluorescent tumor cells were introduced i.v. into mice or rats, and their lungs were isolated and maintained and observed under physiological conditions. Using these methods, we showed that intravascular proliferation rather than early extravasation characterized the initial events in metastatic colony formation. Here, we have adapted these methods to study the initial arrest of tumor cells in the pulmonary vasculature and investigate the role of integrins in this process.

It has long been supposed that integrins play an important role in metastasis. This supposition is based in part on the role of integrins in motility, and in part on data showing that agents that interrupt integrin--ligand interaction also inhibit metastasis. For example, peptides containing the motif RGD (Arg-Gly-Asp) that compete for binding of integrins to fibronectin, or peptides that block binding of integrins to laminin (LN) can inhibit metastasis when coinjected with tumor cells ([@bib18]; [@bib37]; [@bib55]). Antibodies directed against surface integrins that affect LN binding also reduced lung metastasis ([@bib49]). Each integrin is a heterodimer composed of both an α and a β subunit. The ligand-binding domain of the integrin heterodimer is a globular region that requires both subunits to engage the ligand. Thus, antibodies specific for either the α or the β chain can be blocking. Integrins bind to components of ECM such as collagens, fibronectin, and LNs, and can mediate adhesion, spreading, or migration on these substrates ([@bib40]; [@bib48]).

Using an attachment assay based on the observation of fluorescent tumor cells in isolated lungs, we have evaluated the involvement of integrins in the arrest of tumor cells in the pulmonary circulation. This report shows for the first time that the α~3~β~1~ integrin is an important (but not exclusive) component in that process. The importance of α~3~β~1~ integrin in pulmonary vascular attachment by tumor cells raised the question of access to its ligands. LN-5, -8, -10, and -11 are ligands for the α~3~β~1~ integrin ([@bib32]; [@bib14]; [@bib20]; [@bib13]). Each is mainly found in ECM with LN-8/9 and LN-10/11 also present in the stroma of the bone marrow ([@bib42]). How ECM or basement membrane (BM) components could be exposed to tumor cells in pulmonary vessels was not immediately apparent. Unexpectedly, examination of vessels at the sites of tumor cell attachment revealed exposed BM, enabling the binding of α~3~β~1~ integrin.

Results
=======

Assay for tumor cell arrest in the pulmonary vasculature
--------------------------------------------------------

To assess the arrest of tumor cells in the lung, we injected different numbers of fluorescent metastatic HT1080 cells into the renal vein of rats. Immediately after the injection, the isolated, ventilated, and perfused lungs were examined. Fluorescent tumor cells were counted in 60 consecutive nonoverlapping images under low power (10×). The curve of arrested versus injected cells was effectively linear over a range up to 2 × 10^6^ cells. Therefore, injection of cell numbers within the linear range was used in the subsequent experiments to measure pulmonary arrest ([Fig. 1](#fig1){ref-type="fig"} a)

![**Inhibition of pulmonary arrest by anti-**β **integrin antibodies.** HT1080-GFP cells were infused into the renal vein of rats, lungs were isolated, and the number of fluorescent cells in a determined area of the surface was counted as described in the Materials and methods section. (a) Number of HT1080-GFP cells arrested on the surface 30 min after infusion of the indicated cell number. Each point represents the results from three rats. Based on this curve, 3 × 10^5^ HT1080-GFP cells were used in subsequent experiments. (b) Inhibition of pulmonary arrest after pretreatment of HT1080 cells with the indicated blocking antibodies. −, treated without antibody; +, treated with antibody. (c) Effect of infusing the anti-β1 blocking antibody before injection of untreated HT1080 cells. (d) Comparison of the effect on pulmonary arrest of anti-β~1~ blocking antibody to a nonblocking anti-β~1~ antibody.](200309112f1){#fig1}

Effects of integrins on pulmonary attachment in vivo
----------------------------------------------------

HT1080 cells are known to express β~1~, β~3~, β~4~, β~5~, and β~8~, and α~1~, α~2~, α~3~, α~4~, α~5~, α~6~, and α~v~ integrin subunits ([@bib34]). Before i.v. infusion, HT1080-GFP cells were incubated with blocking antibodies to the β~1~, β~3~, or β~4~ integrin subunits or to the α~v~β~5~ integrin. Because blocking antibody to β~8~ integrin is not available, the effect of this integrin was evaluated with the blocking antibody to α~v~, the exclusive heterodimeric partner for the β~8~ integrin subunit ([@bib31]). Of the anti-β subunit antibodies tested, only earlier treatment with anti-β~1~ blocking antibody resulted in a significant reduction in cell attachment ([Fig. 1](#fig1){ref-type="fig"} b). Treatment of HT1080-GFP cells with a nonblocking antibody to β~1~ integrin did not alter pulmonary arrest, nor did infusion of the blocking antibody into the lung before infusion of the tumor cells ([Fig. 1, c and d](#fig1){ref-type="fig"}). These results demonstrated that integrins including the β~1~ subunit were involved in the arrest of HT1080 in the pulmonary vasculature.

HT1080-GFP cells were incubated with blocking antibodies to the α~1~, α~2~, α~3~, α~4~, α~5~, α~6~, or α~v~ integrin subunits. As shown in [Table I](#tbl1){ref-type="table"}, blocking antibodies against the α~1~, α~5~, α~6,~ or α~v~ integrin subunits did not affect pulmonary attachment. Anti-α~3~ integrin subunit antibody had the greatest effect with 34% inhibition, whereas slight reductions of 15 and 16% were seen after the treatments with anti-α~2~ and α~4~ integrin subunits, respectively. The effect of blocking the α~2~ integrin subunit was statistically significant; the effect on the α~4~ integrin subunit was not. Combining these three antibodies increased the inhibition, but was not entirely additive (unpublished data). Blocking antibodies to α~3~ (but not α~6~) integrin subunits similarly reduced pulmonary arrest by two metastatic breast carcinoma cell lines, MDA-MB-231 and MDA-MB-435s ([Table II](#tbl2){ref-type="table"}). Because the α~3~ subunit only forms a complete integrin molecule with the β~1~ subunit, these data suggest that the α~3~β~1~ integrin plays a critical role in the early lodgment of tumor cells in the lung.

###### 

**Effect of anti-**α **integrin subunit blocking antibodies on pulmonary arrest**

  Antibody specificity   Control       Antibody      Inhibition
  ---------------------- ------------- ------------- ------------
  α~1~                   6.00 ± 0.53   5.78 ± 0.65   4
  α~2~                   7.23 ± 0.29   6.10 ± 0.52   15
  α~3~                   7.42 ± 1.07   4.93 ± 1.14   34
  α~4~                   5.95 ± 0.64   5.02 ± 0.66   16
  α~5~                   4.65 ± 1.73   5.03 ± 2.57     −8
  α~6~                   5.94 ± 1.87   6.20 ± 1.83     −5
  α~v~                   6.20 ± 1.50   6.00 ± 2.07   3

HT1080-GFP cells were treated with the indicated blocking antibodies as described in the Materials and methods section. Each value is expressed as cells/mm^2^ ± SD. The anti-α~3~ subunit antibody used was P1B5. Similar results were obtained with ASC-1 (unpublished data). The comparison of means using *t* test was P = 0.03 for α~2~ integrin subunit blocking antibody and P = 0.05 for α~3~. The value for α~4~ was P = 0.15.

###### 

**Effect of** α **integrin subunit blocking antibodies on pulmonary attachment by breast cancer cell lines**

         MDA-MB-231    MDA-MB-435s                                     
  ------ ------------- ------------- ----- ------------- ------------- -----
  α~3~   6.38 ± 0.67   4.74 ± 0.42   26%   7.79 ± 1.36   5.19 ± 0.92   33%
  α~6~   6.45 ± 0.77   6.40 ± 0.61   1%    7.25 ± 1.28   7.22 ± 0.88   0%

The effect of anti-α~3~ or anti-α~6~ subunit blocking antibodies on the breast carcinoma cell lines MDA-MB-231 and MDA-MB-435s was determined as described in the Materials and methods section. Each value is expressed as cells/mm^2^ ± SD.

To further evaluate this hypothesis, the effect of genetic elimination of either the α~3~ or the β~1~ subunit was tested in pulmonary attachment. The β~1~ integrin subunit in ESb cells has been eliminated through homologous recombination at both alleles ([@bib43]). The deficient ESb cells were ∼40% less effective at pulmonary arrest than the parent ESb cells ([Fig. 2](#fig2){ref-type="fig"} a), similar to the result obtained using HT1080-GFP cells treated with blocking antibodies. Restoration of the β~1~ integrin by transfection of a β~1~a cDNA expression vector resulted in the recovery of pulmonary attachment ([Fig. 2](#fig2){ref-type="fig"} a). Likewise, genetic elimination of the α~3~ integrin subunit using immortalized keratinocytes derived from an α~3~ integrin-deficient null mouse (MK 5.4.6^−/−^) resulted in a reduction of 53% in attachment compared with immortalized keratinocytes from a wild-type mouse (MK 1.16^+/+^; [@bib11], [@bib12]). Restoration of α~3~ integrin subunit expression by stable transfection (MK 5.4.6^−/−^ + α~3~) also restored attachment ([Fig. 2](#fig2){ref-type="fig"} b). The role of the α~3~β~1~ integrin in cell attachment was also examined in K562 erythroleukemia cells that have only β~1~ and α~5~ integrin ([@bib8]). Expression of α~3A~ integrin in K562 cells enhanced cell attachment by 40%, but α~6A~ integrin subunit expression had no effect ([Fig. 2](#fig2){ref-type="fig"} c). These data further support the contention that the α~3~β~1~ integrin participates in tumor cell pulmonary attachment.

![**The** α**~3~**β**~1~ integrin contributes to pulmonary arrest in rat lung.** (a) Pulmonary attachment by ESb cells ^(+/+)^, ESb cells without either β~1~ integrin allele ^(−/−)^, or deficient cells reengineered to express β~1~a integrin (^−/−^ + β~1A~). (b) Pulmonary attachment by MK1.16 ^(+/+)^, MK5.4.6 ^(−/−)^ cell without either α~3~ integrin, or deficient cells reengineered to express α~3~ (^−/−^ + α~3~). (c) Pulmonary arrest of K562 parental cells compared with K562 expressing α~3~ or α~6~ integrin subunits.](200309112f2){#fig2}

Anti-α~3~ or anti-β~1~ integrin subunit antibody treatment of HT1080-GFP cells also had an inhibitory effect on early colony formation 1 wk after injection. The cells were exposed to the indicated antibody before injection without any subsequent exposure to the antibody, as in the experiments shown in [Fig. 1](#fig1){ref-type="fig"} b. This initial exposure was sufficient to reduce colony formation. The decrease in colony number exceeded the decrease in pulmonary attachment ([Table III](#tbl3){ref-type="table"}). Initial pulmonary arrest using the α~3~β~1~ integrin appears to play a critical role in subsequent colony formation.

###### Inhibition of early colony formation by pre-treatment with anti-integrin subunit antibodies

  -----------------------------------------------------------------------------------------------------------
  Treatment               Colonies/lung ± SD   Range\             \# of mice   *t* test against no antibody
                                               (\# of colonies)                
  ----------------------- -------------------- ------------------ ------------ ------------------------------
  No antibody             2.25 ± 1.71          0--5               12           \-

  Anti-β~1~ blocking      0                    0                  7            0.001

  Anti-β~1~ nonblocking   2.43 ± 1.72          1--6               7            \-

  Anti-α~3~ (P1B5)        0.71 ± 0.76          0--2               7            0.016

  Anti-α~3~ (ASC-1)       0.71 ± 0.95          0--2               7            0.022

  Anti-α~6~               1.86 ± 2.27          0--5               7            \-
  -----------------------------------------------------------------------------------------------------------

HT1080-GFP cells were treated with the indicated antibodies for 0.5 h before injection as described in the Materials and methods section. After washing, 5 × 10^5^ cells were injected into the tail vein of nu/nu mice. The numbers of colonies were counted after scanning the entire surface of the left lobe of the isolated mouse lung. A two-tailed *t* test is shown only for those with a significant difference as compared to the no antibody control.

α~3~ **β** ~1~ integrin ligands in vivo
---------------------------------------

LN-5 is the best-characterized ligand for the α~3~β~1~ integrin. Because it is mainly a BM component in the lung, we expected that it would be covered by endothelium and not available to circulating tumor cells in the pulmonary vessels ([@bib25]; [@bib10]). To search for LN-5 in vascular channels, we infused two different fluorescently labeled antibodies to the α~3~ chain of LN (MIG-1 and CM6) sequentially after the injection of HT1080-GFP-vimentin cells (these mAbs react with rat, but not mouse LN-5). The α~3~ chain of LN is found in LN-5, -6, and -7 ([@bib9]; [@bib28]). However, LN-5 is considered to be markedly more abundant than the others ([@bib4]). Although MIG-1 generally gave a stronger signal than CM6, both anti-LN-5 antibodies stained small areas surrounding the arrested tumor cells ([Fig. 3](#fig3){ref-type="fig"}, a and b). A similar signal was obtained after the infusion of antibody against the LN γ~2~ chain ([Fig. 3, e and g](#fig3){ref-type="fig"}). The LN γ~2~ chain is unique to LN-5 confirming its presence, but not excluding the presence of LN-6 or -7. GFP-vimentin was used to label the cells because the signal from cytoplasmic GFP alone overwhelmed the signal. To test whether these patches existed before the infusion of tumor cells, fluorescently labeled antibodies to either the α~3~ chain (MIG-1) or the γ~2~ chain of LN were injected into naive rats. Foci of antibody staining were found in lungs ([Fig. 3, c, d, and f](#fig3){ref-type="fig"}). They are infrequent, approximately only on 10--20 high power fields surveyed. Fluorescent antibodies to irrelevant molecules, the cartilage-specific collagen II, or to the platelet integrin αIIb failed to stain any vascular patches ([Fig. 3](#fig3){ref-type="fig"} h). These results have led us to suggest that exposed BM preexists in the pulmonary vasculature.

![**LN-5 can act as a ligand in the pulmonary vasculature.** Immediately after infusion of HT1080-GFP-vimentin cells into rats, the labeled antibodies to LN-5 were infused. 10 min later, the lungs were isolated and perfused. Panels show representative images obtained with labeled (a) anti-LN α~3~ chain antibody (MIG-1), or (b) CM6. (c and d) Typical images seen after infusion of the Alexa Fluor^®^ 647--labeled MIG-1 antibody in naive rats. (e) An image after Alexa Fluor^®^--labeled anti-LN γ~2~ chain antibody staining. The image is a rotation of a three-dimensional reconstruction showing the direct proximity of the γ~2~ staining to the cell. (f) LN γ~2~ chain antibody staining in naive rats. (g) An HT1080-GFP-vimentin cell in a vessel filled with tetramethylrhodamine dextran. LN γ~2~ staining is seen in blue on the vessel wall. (h) Alexa Fluor^®^ control image. (i) Anti-LN α3 chain antibody (CM6) was infused either before or after infusion of HT1080-GFP cells. When antibody infused before, cell attachment was less, P = 0.019. Bars, 20 μm.](200309112f3){#fig3}

To further test the hypothesis that LN-5 acts as a ligand for the α~3~β~1~ integrin on tumor cells, we infused antibodies to the α~3~ chain (CM6) before the injection of HT1080-GFP tumor cells. These antibodies reduced the extent of pulmonary attachment compared with the pulmonary arrest seen when the antibodies were infused after injection of the tumor cells ([Fig. 3](#fig3){ref-type="fig"} i).

Interaction between tumor cells and vascular BM
-----------------------------------------------

We used EM as an alternative means to visualize tumor cell--pulmonary vessel interactions. HT1080-GFP-vimentin cells were labeled with ferritin before injection to allow their identification. 38 tumor cells were identified, all within the pulmonary vessels. Of these, nine cells showed distinct attachment to the vessel wall in EM images. In each of these cases, at the point of contact between the tumor cell and the vessel, the vessel was missing the expected endothelial covering of the basal lamina ([Fig. 4](#fig4){ref-type="fig"}, a--c). When the tumor cells were pretreated with a blocking anti-β~1~integrin subunit antibody, no points of contact were identified (0 out of 33 tumor cells; P = 0.001). Rare patches of exposed BM could be found in the absence of tumor cells ([Fig. 4](#fig4){ref-type="fig"} d). These observations lead to the hypothesis that the foci of exposed BM between endothelial cells may be a prerequisite for tumor cell vascular attachment in the lung.

![**EM shows tumor cells attached to exposed BM.** HT1080-GFP-vimentin cells were exposed to ferritin before injection into rats. Lungs were isolated and fixed with glutaraldehyde by perfusion. (a) A representative image from EM with a tumor cell with internalized ferritin within a small vessel and two contact points seen between the tumor cell and the vessel wall. (b) An enlargement of a contact point. At the contact point, the expected overlying endothelium is absent, showing the tumor cell attached to the BM. (c) A tracing of the structures in b. (d) An incidental portion of exposed BM found in lung not involved by tumor.](200309112f4){#fig4}

Discussion
==========

Our analyses have suggested that tumor cells arrest in the pulmonary vasculature through interaction of their α~3~β~1~ integrin with exposed BM. We have shown that the α~3~β~1~ integrin contributes to metastasis through mediation of early adhesion to the vasculature using a variety of cells, HT1080, MDA-MB-231 and -435s, ESb cells, K562 cells, and immortalized keratinocytes. Interestingly, the α~3~β~1~ integrin is commonly expressed by most tumor cells. In some reports, higher expression of the α~3~β~1~ integrin correlated with increased metastasis ([@bib26]). Involvement of the β~1~ integrin subunit in attachment is consistent with data showing reduced metastasis by a lung carcinoma cell line after treatment with blocking antibodies to the β~1~ integrin subunit ([@bib44]). The α~3~β~1~ integrin associates with the urokinase receptor and with the tetraspanin CD151, both implicated in metastasis ([@bib38]; [@bib47]; [@bib52]; [@bib56]). In keratinocytes, secretion of matrix metalloproteinase-9, a molecule known to influence metastasis, is dependent on the α~3~β~1~ integrin ([@bib12]). Our data further indicate that additional receptors are likely to be involved in pulmonary attachment because partial (rather than complete) blockade of attachment was achieved through inhibition of the α~3~β~1~ integrin.

The observation that antibodies to components of LN-5 stained foci in pulmonary vessels and that anti-LN α~3~ chain antibodies block pulmonary arrest provided evidence for LN-5 as a vascular ligand for the tumor cell α~3~β~1~ integrins. A potential role for LN-6 is not addressed by these analyses. The structural basis for this staining was shown in EM indicating sporadic absence of overlying endothelial cells in small patches in the pulmonary vessels. [@bib22] also found EM evidence for direct contact between tumor cells and pulmonary BM. One might expect that these absences could lead to loss of the fluid barrier. However, in the lung fluid integrity is in fact maintained by the tight junctions of the alveolar cells, not the endothelium ([@bib39]). One might also have expected platelet aggregation. However, the exposure of the surface of the basal lamina or the BM might not expose collagens, or more specifically, their helical domains. In some BMs, the collagens appear to be beneath the basal lamina ([@bib27]). Consistent with this possibility, anti-collagen IV antibody only stained poorly in our hands (unpublished data). This would also explain why the exposed BM regions do not have associated platelet aggregation. Metastasis may favor the lung because of this unique feature of its vessels. Whether arrest in the bone marrow is influenced by the α~3~β~1~ integrin binding with LN-8/9 or LN-10/11 remains to be studied. Other organs may also use different adhesion factors. For example, expression of the α~5~ integrin subunit enhances the arrest of tumor cells in the kidney glomeruli, but does not affect cell attachment in the lung or the liver ([@bib45]).

The α~6~β~4~ integrin also binds to LN-5, yet anti-α~6~ integrin subunit antibody failed to alter attachment in vivo in our experiments. There are other situations in which the α~6~β~4~ integrin and the α~3~β~1~ integrin function differently. Antibodies to the α~3~ integrin subunit blocked migration of pancreatic carcinoma cell lines and inhibited adhesion of keratinocytes to LN-5, whereas antibodies to the α~6~ subunit failed to have these effects ([@bib46]; [@bib15]). The signaling pathways through these two integrins are distinct in keratinocytes ([@bib15]; [@bib24]). The α~6~β~4~ integrin is critical for the formation of hemidesmosomes, whereas the α~3~β~1~ integrin regulates adhesion, spreading, and migration in association with the ECM ([@bib7]). Nonetheless, the α~6~β~4~ integrin clearly plays a role in metastasis, if not a demonstrable role in the early arrest of tumor cells in the lung ([@bib23]; [@bib19]). Metastasis to the mouse lung is inhibited both by pretreatment of the lung with anti-α~6~ integrin subunit antibody and treatment of the tumor cells with the antibody ([@bib36]). Furthermore, α~6~ integrin was shown to contribute to survival of breast carcinoma cells as they formed metastatic colonies ([@bib54]). The α~6~β~1~ can also bind LN-5. Some of the actions attributed to the α~6~ subunit may involve this integrin. Thus, the α~6~ integrin subunit may augment metastasis, not through enhancing pulmonary arrest, but by facilitating survival or proliferation. Pauli\'s group has shown that the β~4~ integrin subunit on tumor cells can ligate to endothelial-bound CLCA1, mediating a signaling cascade that includes FAK activation ([@bib2]). Although they have postulated that this interaction initiates vascular arrest, their data are equally comparable with a model synthesizing our data in which the tumor cell α~3~β~1~ integrin interacts with exposed LN-5, allowing subsequent interactions that then signal for intravascular survival and proliferation. CLCA1 may be one of the factors that contribute to pulmonary arrest in addition to the α~3~β~1~ integrin.

This model is consistent with the observation that pulmonary metastasis is enhanced by endothelial damage. Both hyperoxia and bleomycin or other chemotherapeutic drugs induce endothelial injury and lead to exposure of the BM ([@bib30]; [@bib33]; [@bib21]). [@bib33] demonstrated that endothelial damage with bleomycin promoted pulmonary metastasis, and most of the arrested cells were found attached to the endothelial BM. It has been proposed that tumor cells induce the retraction of endothelial cells, enhancing metastasis ([@bib16], [@bib17]). Our results suggest that LN-5 is available before interaction with tumor cells, but they do not preclude further retraction after arrest.

These analyses put forward a new model for pulmonary metastasis in which tumor cells use the α~3~β~1~ integrin to bind to LN-5 in exposed BM. Colony formation was decreased more extensively than attachment by blockage of the α~3~β~1~ integrin subunits, suggesting that in addition to mediating adhesion, the α~3~β~1~ integrin may also provide important signaling for other steps required for metastasis.

Materials and methods
=====================

Cell lines and culture conditions
---------------------------------

HT1080 cells were transfected with pEGFP-C2 (CLONTECH Laboratories, Inc.; [@bib6]) and pEGFP-vimentin (a gift from Joe Sanger, University of Pennsylvania, Philadelphia, PA), and were screened for fluorescence after selection with 800 μg/ml geneticin. ESb cells (a spontaneous high metastatic variant of Eb that is a chemically induced T cell lymphoma of DBA/2 mice) and derivatives were gifts from E. Roos (Netherlands Cancer Institute, Amsterdam, Netherlands) and were cultured as described previously ([@bib43]). MDA-MB-231 and MDA-MB-435s cell lines were obtained from the American Type Culture Collection and were grown as recommended. Immortalized mouse keratinocyte cell lines (MK cell lines) from wild-type or α~3~-deficient mice were isolated using a temperature-sensitive mutant of SV-40 large T antigen and cultured as described previously ([@bib12]). K562 and K562 expressing the α~3~ or α~6~ integrin subunits generated by [@bib53] were gifts from M. Zutter (Vanderbilt University, Nashville, TN) and A. Sonnenberg (Netherlands Cancer Institute).

Monoclonal antibodies
---------------------

All antibodies used for the tumor cell attachment in vivo assay were purchased from CHEMICON International. The blocking anti-integrin antibodies were as follows: anti-β~1~ from clone 6S6 ([@bib41]); anti-β~3~, clone B3A; anti-β~4~\[CD104\], clone ASC-3; anti-α~v~β~5~, clone P1F6; anti-α~v~, clone AV1; anti-α~1~ I domain, clone FB12; anti-α~2~, clone P1E6; anti-α~3~, clone P1B5 and anti-α~3~, clone ASC ([@bib51]; [@bib50]); anti-α~4~, clone P1H4; anti-α~5~, clone P1D6; and anti-α~6~, clone NK1-GoH3. The anti-β~1~ integrin nonblocking stimulating antibody is clone 21C8.

MIG-1 and CM6 are mouse mAbs raised against different domains of the α~3~ chain of LN-5. Both antibodies react with rat, but not murine LN-5 ([@bib35]; [@bib41]). Anti-LN γ~2~ chain antibody was purchased from CHEMICON International. Antibodies against LNs, or collagen II, were freshly labeled with Zenon mouse IgG labeling kits; Alexa Fluor^®^ 647 (Molecular Probes, Inc.) in a ratio of 10 μg antibody:50 μl labeling reagent:50 μl blocking reagent.

Treatment of cells with antibodies
----------------------------------

Cells were harvested, washed with serum-free medium, and resuspended in the same medium containing 0.1% BSA. The suspensions were incubated with antibodies (10 μg/ml) at 4°C for 30 min on a rotator, followed by dilution with equal volume of the same medium. Although some reports have indicated that treatment with anti-α~3~ integrin subunit antibody can lead to aggregation of keratinocytes ([@bib29]), to ensure that aggregation was not occurring in our experiments, we verified that the cells were in single-cell suspension before injection. As additional confirmation, we point out that we did not see cells in aggregates in the lung after injection.

Intravital attachment test
--------------------------

Tumor cells were labeled by either stable GFP expression (HT1080-GFP and HT1080-GFP-vimentin) or vital fluorescence dyes. ESb cells and derivatives were incubated in 100 μM CellTracker™ Green CMFDA (Molecular Probes, Inc.) in a medium containing 10% FBS at 37°C for 30 min. K562 cells, MK cells, and MDA-MB-231 or -435s cells were labeled with the vital dye MitoTracker^®^ Red CMXRos (200 nM; Molecular Probes, Inc.) by 5 min exposure in culture medium. Experiments using CMFDA or MitoTracker^®^ Red on HT1080-GFP cells gave the same results as monitoring GFP. Male rats (∼250 g; Sprague-Dawley) were injected into the renal vein with 3 × 10^5^ cells unless otherwise indicated. For colony assays, female mice (CD-1 nude; Charles River Laboratories) received 5 × 10^5^ cells in the lateral tail vein. 30 min after injection for the attachment assays or 1 wk after injection for the colony assays, the lungs were ventilated, perfused, and isolated under physiological pressures as described previously ([@bib5], [@bib6]). Fluorescent tumor cells were observed in the isolated lungs using an inverted fluorescent research microscope (model DMIRB; Leica), and images were recorded with a camera (Orca; Hamamatsu Photonics) with OpenLab software (Improvision). The quantitative assays were based on counting cells in 60 consecutive and nonoverlapping fields with a 10×/1× lens (1.1 mm^2^ field/picture). Rats and mice were matched by weight, and each antibody was tested in matched pairs of animals. The results were obtained from at least three independent experiments in all cases.

Confocal scanning laser microscopy
----------------------------------

5 min after injection of HT1080-GFP-vimentin cells (10^6^) into the left renal vein, antibody--Alexa Fluor^®^ complexes were introduced through the inferior vena cava. Lungs were isolated as described above. The pulmonary vasculature was labeled by perfusion with tetramethylrhodamine dextran (Molecular Probes, Inc.). The images were captured using a laser scanning system (Radiance 2000; Bio-Rad Laboratories) and a microscope (Eclipse TE300; Nikon). The 2-line Argon/kryotin laser (wavelength 488 nm/568 nm) and the red laser diode (wavelength 638 nm) were used for observation.

Transmission EM observation
---------------------------

HT1080-GFP-vimentin cells were labeled with the electron-dense marker ferritin at 4°C for 10 min. 5 or 30 min after i.v. injection (2 × 10^6^ cells) into rats, the lung was dissected as described above. Afterwards, the lung was washed with PBS, followed by perfusion with 5% glutaraldehyde. Samples were collected from the upper region of the left lung and fixed in 2.5% glutaraldehyde at 4°C. The images were photographed with a transmission electron microscope, 80 kV (JEM-1010; JEOL USA, Inc.)
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